I

nsys Therapeutics (INSY) agreed on Thursday to pay $500,000 to Massachusetts to resolve charges of illegally marketing its highly addictive Subsys painkiller and paying kickbacks to doctors to write prescriptions.

Between 2012 and 2014, state officials charged that Insys marketed Subsys for patients whose pain is caused by an ailment other than cancer, even though the medicine was only approved by regulators for treating cancer pain. And Insys made misleading statements suggesting that Subsys was appropriate for combating mild pain, even while citing a study that found the drug was only appropriate for “moderate to severe” pain.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy